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Abstract: In view of the pressing need to identify new antibacterial agents able to combat
multidrug-resistant bacteria, we investigated a series of fused selenazolinium derivatives (1–8) regarding
their in vitro antimicrobial activities against 25 ESKAPE-pathogen strains. Ebselen was used as reference
compound. Most of the selenocompounds demonstrated an excellent in vitro activity against all S. aureus
strains, with activities comparable to or even exceeding the one of ebselen. In contrast to ebselen, some
selenazolinium derivatives (1, 3, and 7) even displayed significant actions against all Gram-negative
pathogens tested. The 3-bromo-2-(1-hydroxy-1-methylethyl)[1,2]selenazolo[2,3-a]pyridinium chloride (1)
was particularly active (minimum inhibitory concentrations, MICs: 0.31–1.24 µg/mL for MRSA,
and 0.31–2.48 µg/mL for Gram-negative bacteria) and devoid of any significant mutagenicity in the
Ames assay. Our preliminary mechanistic studies in cell culture indicated that their mode of action
is likely to be associated with an alteration of intracellular levels of glutathione and cysteine thiols
of different proteins in the bacterial cells, hence supporting the idea that such compounds interact
with the intracellular thiolstat. This alteration of pivotal cysteine residues is most likely the result of
a direct or catalytic oxidative modification of such residues by the highly reactive selenium species
(RSeS) employed.
Keywords: selenazolinium salts; ebselen; RSeS; multidrug resistance; MRSA; ESKAPE pathogens;
antibacterial agents
1. Introduction
The emergence and spread of antimicrobial resistance among pathogenic bacteria represents a
major global healthcare problem in the 21st century [1]. A number of common pathogens are reported to
develop resistances against virtually all types or classes of antibiotics [2]. The most troublesome bacteria
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that pose a growing challenge for healthcare practitioners due to their antimicrobial resistance are
referred as ESKAPE pathogens and include vancomycin-resistant enterococci (VRE), methicillin resistant
Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and extended-spectrum β-lactamase (ESBL)-producing or carbapenem-resistant species of the family
Enterobacteriaceae (CRE). The acronym ESKAPE was first proposed by Rice et al. in 2008 to emphasize
the great capacity of these bacteria to “escape” from common antibacterial treatment through rapid
acquisition or development of resistance determinants allowing them to tolerate the antimicrobial
substance(s) [3–6]. Each member of the ESKAPE species is a major source of severe and frequently
lethal diseases in hospitalized patients, and some of them have also successfully spread to community
settings, affecting otherwise healthy individuals [3,7]. Among ESKAPE pathogens, MRSA strains are
the most prevalent Gram-positive bacteria, causing nosocomial infections throughout the world [8,9].
Because of their considerable ability to acquire resistance mechanisms against any antibiotics introduced
into clinical use, the appearance of MRSA strains in hospitals has been associated with substantial
morbidity and mortality rates [9–11]. For multidrug-resistant (MDR) Gram-negative bacteria—namely
A. baumannii, P. aeruginosa, K. pneumoniae, and E. coli, the situation is even more complex and worrisome
as “they represent the problem of multidrug resistance to the maximum” [11]. The therapeutic options
for infections caused by these MDR pathogens are often so extremely limited that, in many cases,
clinicians are left with practically no rational choice of antibiotic treatment [12]. The present situation
is even more threatening when considering the stagnation in the development and approval of novel
antimicrobial agents to treat these pathogens [13]. Therefore, an immediate and continual search for
new antimicrobial agents effective against drug-resistant bacteria, preferentially with a lower risk of
resistance formation, is urgently needed.
In the last few years, selenium-based compounds have received significant attention due to
their unique biological properties which could have multiple prospective applications in clinical
practice [14]. The organoselenium compound ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one,
Figure 1), in particular, is a promising agent for the therapy of various health disorders [15,16]
and is presently undergoing Phase III clinical trials in patients suffering from acute ischemic
stroke and cortical infarct due to its pharmacological efficacy and favourable safety profile [17,18].
Ebselen, like many other organic selenium compounds, is redox-active and able to modify cysteine
residues in proteins and enzymes effectively and selectively. In the presence of elevated levels of
reactive oxygen species (ROS), it can also “turn catalytic”, and its pronounced glutathione peroxidase
(GPx)-like activity promotes widespread interactions with cysteine residues of proteins belonging
to the cellular thiolstat [19], hence resulting in significant decreases of intracellular protein thiols
and activation of various redox-controlled cellular pathways [20]. In addition to various pro- and
antioxidant actions associated traditionally with ebselen, recent studies have also discovered an
excellent bactericidal action against the Gram-positive ESKAPE species E. faecalis/E. faecium and
S. aureus. Curiously, ebselen lacks any major activity against Gram-negative ESKAPE pathogens [21].
This may not be extraordinarily surprising, as ebselen is not the most reactive amongst the selenium
compounds frequently discussed today.
The overarching rationale of this study has therefore been the evaluation of ebselen-like selenium
compounds with similar structural features and specificity towards nucleophilic attack by thiols,
yet with improved reactivity. Within this context, one particular strategy to “improve” the reactivity
of the Se–N bond towards cysteine thiols is the introduction of a positive charge which increases the
electrophilic behaviour of the bond.
As part of this strategy, and during the search for new ebselen analogues containing fused rings
with an endocyclic Se–N bond, a series of selenazolinium salts were obtained [22]. Eight of these
compounds (1–8, Figure 1), have been investigated here for their antibacterial properties against a
variety of S. aureus clinical isolates, as well as representative strains of clinically relevant Gram-negative
ESKAPE bacteria. In addition, initial pharmaceutical safety studies have been carried out, and the
most active compounds have been investigated regarding their potential mechanisms of action.
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Figure 1. Chemical structures of ebselen (in the insert) and the selenazolinium salts 1–8 investigated. 
2. Results and Discussion 
2.1. Chemical Synthesis 
Synthesis of 3-bromo-selenazolopyridinium chlorides 1–7 and 3-bromo-2-(1-hydroxycyclohexyl) 
[1,2]selenazolo[2,3-b]thiazolinium chloride 8 (Figure 1) was described elsewhere [22]. 
2.2. In Vitro Antibacterial Activity 
The in vitro antibacterial activities of the selenazolinium compounds (1–8) were evaluated for 
25 strains of ESKAPE bacteria, including 11 Gram-positive strains (Table 1) and 14 Gram-negative 
microbes (Table 2) with a variety of clinical characteristics. 
Table 1. Characteristics of the ESKAPE Gram-positive strains used in this study. 
Bacterial Strain Relevant Phenotype *
Staphylococcus aureus  
ATCC 25923 Reference strain, CC5, MSSA 
MM-O058 Clinical isolate, CC121, MSSA, MDR 
MM-N072 Clinical isolate, CC152, MSSA, MDR 
HEMSA 5 Clinical isolate, MRSA, XDR 
LG-N017 Clinical isolate, CC5, MRSA, MDR 
MM-O021 Clinical isolate, CC8, MRSA, MDR 
R45-CC45 Clinical isolate, CC45, MRSA 
R46-CC22 Clinical isolate, CC22, MRSA 
USA300 LAC Clinical isolate, CC8, CA-MRSA, MDR 
5328 Clinical isolate, CC398, LA-MRSA 
Mu50 Clinical isolate, CC5, MRSA, VISA 
* CC, clonal complex; MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; 
CA-MRSA, community-acquired MRSA; LA-MRSA, livestock-associated MRSA; VISA, vancomycin-
intermediate S. aureus; MDR, multidrug-resistant; XDR, extensively drug-resistant [23]. 
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3-bromo-2-(1-hydroxycyclohexyl)[1,2]sel nazolo[2,3-b]thiazolinium chloride 8 (Figure 1) was
described elsewhere [22].
2.2. In Vitro Antibacterial Activity
The in vitro antibacterial activities of the selenazolinium compounds (1–8) were evaluated for
25 strains of ESKAPE b cteria, including 11 G m-pos tive strains (Table 1) and 14 Gram-negative
microbes (Table 2) with a variety of clinical characteristics.
Table 1. Characteristics of the ESKAPE Gram-positive strains used in this study.
Bacterial Strain Relevant Phenotype *
Staphylococcus aureus
ATCC 25923 Reference strain, CC5, MSSA
MM-O058 Clinical isolate, CC121, MSSA, MDR
MM-N072 Clinical isolate, CC152, MSSA, MDR
HEMSA 5 Clinical isolate, MRSA, XDR
LG-N017 Clinical isolate, CC5, MRSA, MDR
MM-O021 Clinical isolate, CC8, MRSA, MDR
R45-CC45 Clinical isolate, CC45, MRSA
R46-CC22 Clinical isolate, CC22, MRSA
USA300 LAC Clinical isolate, CC8, CA-MRSA, MDR
5328 Clinical isolate, CC398, LA-MRSA
Mu50 Clinical isolate, CC5, MRSA, VISA
* CC, clonal complex; MSSA, methicillin-susceptible S. aureus; MRSA, meth cillin-resistant S. aureus; CA-MRSA,
community-acquired MRSA; LA-MRSA, livestock-associated MRSA; VISA, vancomycin-intermediate S. aureus;
MDR, multidrug-resistant; XDR, extensively drug-resistant [23].
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Table 2. Characteristics of the ESKAPE Gram-negative strains used in this study.
Bacterial Strain Relevant Phenotype
Klebsiella pneumoniae
NRZ-00103 Reference strain, KPC-2, MDR, 4 MRGN
KP 21513017 Clinical isolate
KP 1963584 Clinical isolate, OXA-2, MDR, 4 MRGN
Acinetobacter spp.
AC 2151300 Clinical isolate, A. ursingii
AC 1995594 Clinical isolate, A. baumannii complex
AB 4184/2/5 Clinical isolate, A. baumannii
Pseudomonas aeruginosa
ATCC 27853 Reference strain
PA T18 Clinical isolate, MDR, 3 MRGN
PA 54 Clinical isolate, MDR
PA 58 Clinical isolate, MDR
Escherichia coli
NCTC 13351 Reference strain, TEM-3
EC 2151612 Clinical isolate, MDR, 3 MRGN
EC 1995591 Clinical isolate, MDR, 3 MRGN
EC 1227107 Clinical isolate, MDR, 3 MRGN
3/4 MRGN bacteria, multidrug-resistant Gram-negative bacteria. The description 3 or 4 MRGN refers to the
classification of multidrug-resistant Gram-negative bacteria created by the Commission for Hospital Hygiene and
Infectious Disease Prevention (KRINKO) of the Robert Koch-Institute (RKI) in order to outline the resistance pattern
of these pathogens. Bacteria identified as 3 or 4 MRGN are resistant to three or four out of four classes of antibiotic
groups used in the treatment of infections that they cause, respectively [24]; KPC-2, carbapenemase KPC-2; OXA-2,
β-lactamase OXA-2; TEM-3, extended-spectrum β-lactamase TEM-3.
2.2.1. Antibacterial Activity against S. aureus Strains
Antimicrobial activities of compounds 1–8 were investigated against 11 strains of S. aureus
(Gram-positive bacteria) in comparison to ebselen and oxacillin. (Table 3). Results demonstrate that all
selenocompounds (1–8) exhibited excellent antibacterial activities against all S. aureus strains employed
in this study, with MIC values (0.31–3.44 µg/mL) in a similar range as that of ebselen (0.28–2.24 µg/mL).
The same antibacterial effect of compounds 1–8 was observed against both the methicillin-susceptible
S. aureus isolates ATCC 25923, MM-O058, and MM-N072 (MICs = 0.35–3.44 µg/mL) as well as
the methicillin-resistant S. aureus isolates USA300 LAC (CA-MRSA), 5328 (LA-MRSA), LG-N017,
MM-O021, R45 CC22, R45 CC45, HEMSA 5 (HA-MRSA), and Mu50 (VISA) (MIC = 0.31–3.44 µg/mL).
Most of the compounds, except the aldehyde analogue (5), were more active against all MDR and XDR
strains as compared to the reference strain (ATCC 25923, Table 3). This selectivity for the MDR and
XDR (extensively drug-resistant) strains—paired with high activity at low concentrations—turns these
compounds into a promising tool in the fight against drug-resistant bacteria [23]. Moreover, in all cases,
compounds 1–8 exhibited significantly higher antimicrobial activity against MRSA clinical isolates
when compared to the standard drug oxacillin. Among selenazolinium salts, compounds 1 and 6
represented the most effective antimicrobials with MIC values below 1 µg/mL against all but one
MRSA strain, namely HEMSA 5.
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Table 3. Antibacterial activities (MICs) of compounds 1–8 against different strains of S. aureus.
S. aureus Strain
MIC (µg/mL)
OXA 1 2 3 4 5 6 7 8 Ebselen
ATCC 25923 0.25 1.24 1.72–3.44 1.4 1.45 0.72–1.44 0.36–0.72 1.44–2.88 2.88 0.56
MM-O058 * 0.25 0.62 0.86 0.35–0.7 0.36–0.73 0.72 0.36–0.72 0.36–0.72 0.36–0.72 0.56–1.12
MM-N072 * 0.25 0.62–1.24 3.44 0.7–1.4 0.73–1.46 0.72 0.36–0.72 0.72 1.44–2.88 0.56–1.12
USA300 LAC * 12 0.62 3.44 0.7 0.73 0.72–1.44 0.72–1.44 0.36–0.72 0.72–1.44 0.56–1.12
5328 4 0.62–1.24 3.44 1.4 1.45 1.44–2.88 0.72–1.44 0.72–1.44 1.44–2.88 1.12–2.24
LG-N017 * 12 0.62–1.24 0.86–1.72 0.35–0.7 0.73–1.45 0.72–1.44 0.36–0.72 0.36–1.44 0.72–1.44 1.12–2.24
MM-O021 * 64 0.31–0.62 1.72–3.44 0.35–0.7 0.36–0.73 0.36–0.72 0.36–0.72 0.36–0.72 0.72–1.44 0.56–1.12
R45 CC22 64 0.31 0.86–1.72 0.35 0.36–0.73 0.36–0.72 0.36 0.36–0.72 0.36–0.72 1.12
R45 CC45 4 0.31–0.62 1.72–3.44 0.7–1.4 0.36–0.73 0.72 0.36–0.72 0.72 1.44 0.56
HEMSA 5 ** 128 1.24 1.72 1.4 1.45 1.44 0.72 0.72–1.44 2.88 2.8
Mu50 *** 256 0.31–0.62 0.43–0.86 0.7–1.4 0.36–0.73 0.36–0.72 0.36 0.36–0.72 0.72–1.44 0.28
* MDR, multidrug-resistant isolates; ** XDR, extensively drug-resistant isolate; *** VISA strain. Oxacillin (OXA) was used as reference β-lactam antibiotic.
Molecules 2017, 22, 2174 6 of 16
2.2.2. Antibacterial Activity against Gram-Negative Bacteria
Subsequently, selenocompounds 1–8 were evaluated for their possible inhibitory effects against
four particularly problematic Gram-negative bacterial species belonging to ESKAPE pathogens
(Table 2), and compared to ebselen (Table 4). At least three isolates of K. pneumoniae, Acinetobacter spp.,
P. aeruginosa, and E. coli, including 3 or 4 MRGN strains, were employed in the MIC experiments.
Bacteria identified as 3 or 4 MRGN are resistant to three or four out of four classes of antibiotic groups
used in the treatment of infections that they cause, respectively [24].
Compounds with MICs < 5 µg/mL were considered as highly active ones. In stark contrast
to ebselen, all selenoazolinium salts (1–8) exhibited significant antibacterial activities against at
least two Gram-negative ESKAPE strains. The highest sensibility for compounds 1–8 was observed
for Acinetobacter spp., whereas the reference strain of P. aeruginosa (ATCC 27853) was sensitive
only to compound 1. Interestingly, compounds 1–8 were significantly more active in case of
MDR P. aeruginosa strains when compared to the reference strain. Apart from the ATCC 27853
strain, all selenoazolinium compounds (1–8) exhibited MICs significantly lower than those of
ebselen. Among the selenazolinium salts, compound 1 demonstrated excellent activities against
all ESKAPE strains tested (MICs = 0.31–2.48 µg/mL). A high antibacterial potency was also observed
for compounds 3, 4, and 7, as these selenium compounds were active against 3 MRGN strains of E. coli
and the 4 MRGN K. pneumoniae isolate (Table 4).
2.3. Results of Pharmaceutical Safety
In order to assess some central drug-safety properties for the selenium agents (1–8 and ebselen),
and bearing in mind that certain inorganic-selenium compounds such as selenite (SeO32−) interact
unfavourably with DNA, all relevant compounds were investigated for their possible mutagenic
properties in vitro employing the microtiter Ames test [25–29].
Each experiment was performed in triplicate, and results were given in terms of mutagenic index
(MI), which is the quotient of the number of revertant colonies induced in a test sample and the number
of revertants in a negative control (media with 1% DMSO). A compound is considered mutagenic if MI
is above 2.0 [30,31]. According to the results obtained (Figure 2), neither selenazolinium salts (1–8) nor
ebselen appeared to cause any significant mutagenic changes at the concentrations used (1 µM and 10 µM),
resulting in MI below 2.0, whereas the MI value for reference NQNO (0.5 µM) was 7.24 (Table 5).
When comparing the MI values obtained between the two concentrations tested (1 µM and 10 µM),
however, an evident decrease of MI values for the higher concentration of compounds 4–8 can be noted
(Table 5). This decrease is connected with the cytotoxic activity of 4–8 against the Salmonella typhimurium
TA100 strain, confirmed at 10 µM by Binominal B-values calculated according the manufacturer protocol,
where B ≤ 0.01 indicates the occurrence of cytotoxic events (Figure 2, Table 5).
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Table 4. MIC values of the compounds 1–8 and ebselen against Gram-negative ESKAPE strains.
Bacterial Strain
MIC (µg/mL)
1 2 3 4 5 6 7 8 Ebselen
K. pneumoniae
1 1.24 * 14 1.4–2.8 2.88–5.76 46 46 2.88 5.76 ≥143
2 0.62–1.24 6.88–14 1.4 2.88 35 17 2.88 5.76 108
3 0.62 6.88 1.4 2.88 17 17 1.44–2.88 2.88 72
Acinetobacter spp.
4 0.31–0.62 0.86 0.35–0.7 0.36–0.72 2.88 1.44 0.36–0.72 1.44 18
5 0.62 1.72–3.44 1.4 0.72 2.88–5.76 2.88 0.72 1.44–2.88 27
6 0.31 0.86 0.35 0.36 2.88 0.72–1.44 0.36 1.44 18
P. aeruginosa
7 2.48 110 5.60–11 5.76–12 69 138 17 23 72
8 0.31 1.72 0.7 1.44 12 12 0.72 1.44–2.88 18
9 0.62–1.24 21 1.4–2.8 5.76 12 69 5.76 5.76–12 108
10 0.62 6.88–14 1.4 2.88 17 23 2.88 5.76 27
E. coli
11 1.24–2.48 6.88–14 1.4 2.88 17 12 2.88 5.76 108
12 1.24–2.48 6.88 1.4 2.88 17 12 1.44–2.88 5.76 72
13 2.48 6.88–14 1.44–2.8 2.88 23 12 2.88 5.76 72
14 1.24–2.48 14 2.8 5.76 23 17 2.88 5.76–12 54
* Particularly potent antibacterial activities (MIC < 5 µg/mL) are underlined. In case of MIC ≥ 10 µg/mL, the MIC values are expressed rounded to integers (see Supplementary for details).
Bacterial strains—K. pneumoniae: (1) NRZ-00103, (2) KP 21513017, (3) KP 1963584; Acinetobacter spp.: (4) AC 2151300, (5) AB 1995594, (6) AB 4184/2/5; P. aeruginosa: (7) ATCC 27853,
(8) PA T18, (9) PA54, (10) PA58; E. coli: (11) NCTC 13351, (12) EC 2151612, (13) EC 1995591, (14) EC 1227107.
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Figure 2. Results of the Ames liquid microtiter test and determination of the mutagenic potential; 
DMSO (1%)—negative control; ebselen-reference compound; NQNO (4-nitroquinoline-N-oxide)—
mutagenic agent at concentration 0.5 µM; 1–8—selenocompounds at concentrations 1 µM and 10 µM, 
respectively; —baseline defining the mutagenicity threshold (over the line). 
Table 5. Mutagenic index (MI) values for ebselen and tested compounds (1–8). 
Cpd. MI (1 µM) B MI (10 µM) B
Ebselen 0.69 0.26 0.80 0.46 
1 0.69 0.35 1.60 1.00 
2 0.96 0.83 1.49 1.00 
3 1.97 0.99 0.48 0.06 
4 1.49 0.71 0.16 0.00 
5 1.81 0.96 0.05 0.00 
6 1.33 0.97 0.32 0.00 
7 1.28 0.94 0.16 0.00 
8 1.28 0.98 0.05 0.00 
MI—mutagenic index values for ebselen and selenocompounds 1–8, B—Binomial B-value. 
2.4. Studies on the Possible Mode of Antimicrobial Action 
Whilst the results obtained so far point towards a considerable and widespread antibacterial 
activity associated with virtually all of the selenazolinium compounds under investigation, they do not 
reveal any information regarding the possible underlying mode(s) of action. Based on the chemical 
structures of these compounds, and their particular reactivity as thiol-selective electrophiles, one may 
expect a certain “redox link” that has been investigated in more detail. Such a link may constitute, 
for instance, in the production of ROS, a loss of thiols or a—possibly catalytic—oxidation of specific 
thiol groups in particularly redox-sensitive proteins and enzymes of the cellular thiolstat [32–34]. 
2.4.1. Evaluation of ROS Formation 
In order to analyse the effect of the selenazolinium salts (1–8) on intracellular oxidative stress 
production in S. aureus, the 2′,7′-dichlorofluorescein diacetate assay (DCFH-DA assay) was performed. 
This assay is used routinely in the context of human cell culture and can also be applied to bacteria. 
For this purpose, the impact of the most active compounds identified in the MICs assays (1 and 6) 
and ebselen on intracellular ROS concentrations was determined with the reference S. aureus strain 
ATCC 25923 and the clinical XDR-MRSA isolate HEMSA 5 (Figures S1–S3, Supplementary section). 
Figure 2. Results of the Ames liquid microtiter test and determination of the
mutagenic potential; DMSO (1%)—negative control; ebselen-reference compound;
NQNO (4-nitroquinoline-N-oxide)—mutagenic agent at concentration 0.5 µM; 1–8—selenocompounds
at concentrations 1 µM and 10 µM, respectively; —baseline defining the mutagenicity threshold
(over the line).
Table 5. Mutagenic index (MI) values for ebselen and tested compounds (1–8).
Cpd. MI (1 µM) B MI (10 µM) B
Ebselen 0.69 0.26 0.80 0.46
1 0.69 0.35 1.60 1.00
2 0.96 0.83 1.49 1.00
3 1.97 0.99 0.48 0.06
4 1.49 0.71 0.16 0.00
5 1.81 0.96 0.05 0.00
6 1.33 . 7 0.32 0.00
7 1.28 0.94 0.16 0.00
8 1.28 0.98 0.05 0.00
MI—mutagenic index values for ebselen and selenocompounds 1–8, B—Binomial B-value.
2.4. Studies on the Possible Mode of Antimicrobial Action
Whilst the results obtained so far point towards a considerable and widespread antibacterial
activity associated with virtually all of the selenazolinium compounds under investigation, they do
not reveal any information regarding the possible underlying mode(s) of action. Based on the chemical
structures of these compounds, and their particular reactivity as thiol-selective electrophiles, one may
expect a cert in “redox link” th has been investigated in more detail. Such a link may constitute,
for instance, in the production of ROS, a loss of thiols or a—possibly catalytic—oxidation of specific
thiol groups in particularly redox-sensitive proteins and enzymes of the cellular thiolstat [32–34].
2.4.1. Evaluation of ROS Formation
In order to analyse the effect of the selenazolinium salts (1–8) on intracellular oxidative stress
production in S. aureus, the 2′,7′-dichlorofluorescein diacetate assay (DCFH-DA assay) was performed.
This assay is used routinely in the context of human cell culture and can also be applied to bacteria.
For this purpose, the impact of the most active compounds identified in the MICs assays (1 and 6)
and ebselen on intracellular ROS concentrations was determined with the reference S. aureus strain
ATCC 25923 and the clinical XDR-MRSA isolate HEMSA 5 (Figures S1–S3, Supplementary section).
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Rather unexpectedly, we observed that neither compound 1 nor compound 6 were able to increase
ROS levels in the S. aureus isolates tested.
2.4.2. Reactivity of the Compounds with Thiol Groups
Recent studies have shown that many chalcogen compounds do not generate ROS per se but
instead interfere with their removal by consuming thiol groups [35–37]. Indeed, selenium-based
molecules have been reported to spontaneously react with various biological thiols, including GSH
and cysteine-containing proteins. We therefore performed a standard Ellman’s Reagent DTNB assay in
order to explore the consumption of thiols as possible mode of antibacterial activity of the compounds
tested (Figure 3).
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Figure 3. Estimation of levels of thiol residues of 100 µM N-acetyl-L-cysteine in the presence of 
different concentrations of compounds 1, 6, or ebselen by the DTNB assay. Hydrogen peroxide served 
as positive control in the study. The decrease in 2-nitro-5-thiobenzoate (TNB) indicates the ability of 
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The ability of the selenium-based compounds to consume thiol groups was determined with  
N-acetyl-L-cysteine, which was exposed to the compounds and whose remaining thiol groups were 
subsequently quantified with Ellman’s Reagent DTNB. A loss in thiol groups due to the presence of 
the selenium compounds would be noted by less TNB production assuming that the products of the 
reaction of N-acetyl-L-cysteine with the selenium compounds do not react with DTNB. As shown in 
Figure 3, the addition of the compounds (1 and 6) at concentrations as low as ≤50 µM to the N-acetyl-
L-cysteine solution significantly decreased the levels of TNB, indicating that the compounds are able 
to modify cysteine, and hence may also be able to attack various proteins and enzymes of the cellular 
thiolstat of the bacteria. The cysteine-modifying activities of the compounds were comparable to or 
even higher than one of the reference molecules—hydrogen peroxide. Interestingly, the more 
pronounced effect was observed for compound 1—which was also very active against bacteria—
followed by ebselen and, to a lesser extent, by compound 6. 
2.5. Structure–Activity Relationship Discussion 
Overall, the studies performed with selenazolinium salts 1–8 have identified this rather unusual 
class of selenium compounds as very reactive chemically and very active biologically. It is highly 
probable that the extraordinary electrophilic behaviour associated with the positively charged Se–N 
Figure 3. Estimation of levels of thiol residues of 100 µM N-acetyl-L-cysteine in the presence of
different concentrations of compounds 1, 6, or ebselen by the DTNB assay. Hydrogen peroxide served
as positive control in the study. The decrease in 2-nitro-5-thiobenzoate (TNB) indicates the ability of the
compounds/H2O2 to modify free sulfhydryl groups of various amino acids of the proteins. It should be
noted that compounds have been added in substoichiometric amounts compared to N-acetyl-L-cysteine
to account for possible thiol oxidation cascades. Statistical significance was assessed by one-way
ANOVA (mean ± SD, n = 5 replicates) followed by Dunnett’s multiple comparisons test. * p ≤ 0.05,
** p ≤ 0.01 and **** p ≤ 0.0001 compared with the control.
The ability of the selenium-based compounds to consume thiol groups was determined with
N-acetyl-L-cysteine, which was exposed to the compounds and whose remaining thiol groups
were subsequently quantified with Ellman’s Reagent DTNB. A loss in thiol groups due to the
presence of the selenium compounds would be noted by less TNB production assuming that
the products of the reaction of N-acetyl-L-cysteine with the selenium compounds do not react
with DTNB. As shown in Figure 3, the addition of the compounds (1 and 6) at concentrations
as low as ≤50 µM to the N-acetyl-L-cysteine solution significantly decreased the levels of TNB,
indicating that the compounds are able to modify cysteine, and hence may also be able to attack
various proteins and enzymes of the cellular thiolstat of the bacteria. The cysteine-modifying activities
of the compounds were comparable to or even higher than one of the reference molecules—hydrogen
peroxide. Interestingly, the more pronounced effect was observed for compound 1—which was also
very active against bacteria—followed by ebselen and, to a lesser extent, by compound 6.
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2.5. Structure–Activity Relationship Discussion
Overall, the studies performed with selenazolinium salts 1–8 have identified this
rather unusual class of selenium compounds as very reactive chemically and very active
biologically. It is highly probable that the extraordinary electrophilic behaviour associated
with the positively charged Se–N motif is responsible for the excellent growth inhibitory
activities on all MDR S. aureus strains. Indeed, the selenazolinium salts 1–8 showed a
comparable influence on S. aureus, often exceeding the one of ebselen, and in all MRSA
strains were considerably more active when compared to the standard antibiotic oxacillin.
Two compounds, the 3-bromo-2-(1-hydroxy-1-methylethyl)[1,2]selenazolo[2,3-a]pyridinium chloride (1)
and the 3-bromo-2-(1-hydroxycyclohexyl)-7-(2-hydroxypropan-2-yl)[1,2]selenazolo[2,3-a]pyridinium
chloride (6) displayed an even stronger antimicrobial effect than ebselen against two of the MRSA strains
tested (LG-N017 and R45 CC22). It is worth emphasizing that their antistaphylococcal activities in form
of MICs are superior to those recently reported for fluoroquinolones and their thiolated analogues [5].
Indeed, the activity of the selenazolinium salts is comparable to that of the most active agents produced
by the latest lines of investigation, e.g., 9,13-disubstituted berberine derivatives [38] or polyhalogenated
2-phenylbenzimidazoles [39].
The studies on the possible mechanisms of action against MRSA strains identified a similar
behaviour of the selenazolinium compounds (1 and 6) and ebselen in all three assays indicating
that the mode of action of the compounds is related to an extensive modification of thiol groups,
possibly in cysteine-containing cellular proteins that are crucial for bacterial survival and growth.
Interestingly, in both cases, i.e., the 3-bromo-selenoazolinium compounds and ebselen, there was only
a slight strain-related discrimination in the antibacterial effects observed, and an even more potent
efficacy in the case of MDR bacteria than in the corresponding reference strains. In contrast to oxacillin,
it is possible that such Se–N endocyclic selenocompounds can overcome certain MDR mechanisms.
There may be various reasons for such behaviour. One may, for instance, consider a widespread and
simultaneous attack of such reactive selenium compounds on various redox-sensitive cysteine proteins,
hence avoiding the kind of resistance associated with “single target” drugs. Alternatively, a significant
consumption of cellular thiols may also trigger unfavourable intracellular signalling processes
which may eventually harm the bacterium affected. In any case, the considerably high activity,
especially against MDR-strains, is of great interest for the current search of antimicrobial agents.
Here, an even more important finding of these studies is the high potency of the
compounds 1–8 against Gram-negative ESKAPE bacteria, which clearly distinguishes these
selenazolinium compounds from ebselen and places them on par with the best anti-ESKAPE
agents found recently, such as isothiazolone [40] or bis-cyclic guanidine compounds [41].
The results obtained here with 14 different Gram-negative strains evidently confirm the promising
properties of the entire group of both, the 3-bromo-selenazolopyridinium chlorides (1–7) and
3-bromo-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-b]thiazolinium chloride (8), against both types
of ESKAPE strains, with special accent on the selenazolopyridinium compounds 1 and 3 (Figure 1,
Tables 2 and 3).
Although it is difficult to discuss probable mechanisms of action, in this case, it is rather obvious
that the charged endocyclic Se–N bond is beneficial for the action against Gram-negative pathogens.
In contrast, ebselen is not active against the latter group of bacteria. Nonetheless, not all selenazolinium
salts were equally active and some differences in activity have been observed within the group (1–8).
Thus, decreased activities were observed for the hydroxycyclohexyl derivatives substituted at position 7
with formyl (5) or hydroxyl-alkyl (6) moieties. A very simple structure–activity relationship (SAR)
analysis suggests that substituents at the pyridine part of the fused rings of compounds 1–7 may
influence the action on Gram-negative pathogens. Thus, a substitution at position 7 could be responsible
for a decrease of antibacterial action. The most active compounds 1 and 3 are not substituted
within the pyridine part of the fused rings as well as they include 1-hydroxy-1-methylethyl- or
1-hydroxycyclohexyl terminal fragments, respectively (Figure 1, Tables 2 and 3). It is not entirely
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clear yet, however, which of the structural properties are really responsible for the outstanding
action observed for some of the compounds, since both the unsubstituted pyridine fragment and the
1-hydroxycyclohexyl one are also present in the less active compounds (2, 4–6 and 8, respectively).
In the case of activity against S. aureus, the most active compounds (1 and 6) are also the more
hydrophilic. The first one (1) possesses the smallest acyclic alcohol moiety, whereas compound 6
includes two hydroxyl groups.
The excellent results obtained for compounds 1–8 in the assays against a panel of 25 ESKAPE
bacterial strains demands further studies for this group of unique compounds in order to evaluate the
pharmaceutical safety profile. In this context, we have already applied the Ames mutagenicity assays,
a gold standard in the initial steps of drug R&D process. The results of low mutagenicity risk for
compounds 1–8 obtained, in resemblance to ebselen, indicate that the new selenazolinium compounds
can be considered as potential candidates for a new drug that is successful in the battle against the
most problematic multidrug-resistant pathogens. Still, a high electrophilic reactivity may also imply a
more random reactivity, for instance, also against human cells, and such issues related to selectivity
should be considered in future studies.
3. Materials and Methods
3.1. Microbiological Assays
3.1.1. Chemical Compounds
The selenazolinium salts: 3-bromo-2-(1-hydroxy-1-methylethyl)[1,2]selenazolo[2,3-a]pyridinium
chloride (1), 3-bromo-2-(1-hydroxy-1-phenylethyl)[1,2]selenazolo[2,3-a]pyridinium
chloride (2), 3-bromo-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-a]pyridinium chloride (3),
3-bromo-2-(1-hydroxycyclohexyl)-5-methyl[1,2]selenazolo[2,3-a]pyridinium chloride (4),
3-bromo-7-formyl-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-a]pyridinium chloride (5),
3-bromo-2-(1-hydroxycyclohexyl)-7-(2-hydroxypropan-2-yl)[1,2]selenazolo[2,3-a]pyridinium
chloride (6), 3-bromo-2-(1-hydroxycycloheptyl)[1,2]selenazolo[2,3-a]pyridinium chloride (7),
and 3-bromo-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-b]thiazolinium chloride (8) were synthesized
according to the procedures described previously [22].
Ebselen was purchased from Sigma-Aldrich (St. Louis, MO, USA). The stock solutions
of the compounds tested were prepared in DMSO/H2O and stored at −20 ◦C until used.
Furthermore, the following solvents and chemical compounds were employed in our studies:
2′,7′-dichlorofluorescein diacetate (DCFH-DA) and oxacillin (Sigma-Aldrich, St. Louis, MO, USA);
2-azobis(2-amidinopropane) dihydrochloride (AAPH; Sigma-Aldrich, Steinheim, Germany);
H2O2 (Life Technologies, Eugene, OR, USA); 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, Ellman reagent;
Sigma-Aldrich, St. Louis, MO, USA); N-acetyl-L-cysteine (Alfa-Aesar, Karlsruhe, Germany);
ampicillin (Polfa Tarchomin S.A., Warszawa, Poland); 4-nitroquinoline-N-oxide (NQNO; Sigma-Aldrich,
Munich, Germany); DMSO and bromocresol purple (Sigma-Aldrich, Munich, Germany); Beef extract,
L-histidine monochloride, and D-biotin (Bioshop, 5480 Mainway, Burlington, Ontario, Canada); peptone
from casein (Merck, Darmstadt, Germany); KH2PO4, K3PO4, (NH4)2SO4, MgSO4 × 7H2O, NaCl,
trisodium citrate dehydrate, and D-glucose (Chempur, Piekary Śląskie, Poland).
3.1.2. Bacterial Strains
Twenty-five bacterial strains used in this study are listed in Table 1. S. aureus ATCC®25923TM and
MRSA HEMSA 5 were obtained from the Institute of Hygiene and Tropical Medicine, Universidade
Nova de Lisboa, Lisbon, Portugal; and the A. baumannii isolate AB 4184/2/5 was obtained from
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Jagiellonian University Medical
College, Cracow, Poland. The remaining bacterial strains were obtained from the stock collection
of the Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
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S. typhimurium TA100 strain (Xenometrix, Allschwil, Switzerland) with the base pair substitution
(hisG46 mutation, which target is GGG) was used for the Ames assays indicative of mutagenicity.
3.1.3. Antimicrobial Susceptibility Testing
The minimal inhibitory concentration tests were performed by the standard microdilution method
in cation-adjusted Mueller Hinton II Broth (MHB II, Becton-Dickinson, Heidelberg, Germany) according
to Clinical and Laboratory Standards Institute (CLSI) recommendations [42]. Antibacterial activities
against S. aureus strains were evaluated in comparison with the β-lactam antibiotic oxacillin. The MICs
of compounds 1–8 and ebselen were recorded after 20 h incubation at 37 ◦C. The antibacterial effect
was determined in triplicate in at least three independent experiments.
3.1.4. Determination of Intracellular Oxidative Stress Levels via the DCFH-DA Assay
Reactive oxygen species (ROS) production in S. aureus strains ATCC 25923 and MRSA HEMSA 5
under exposure to a given selenium compound was measured by using the redox-sensitive fluorescent
indicator dye DCFH-DA, according to the protocol published previously [43]. The concentrations of the
compounds were used at levels ranging from 1/2 to 2× their MICs. AAPH at the final concentration of
50 mM was included as positive control in the assay. The fluorescence intensity was detected at 5 min
intervals over a 60 min period using a microplate reader (EnSpire, PerkinElmer, Waltham, MA, USA),
with an excitation wavelength of λex = 480 nm and an emission wavelength of λem = 525 nm.
3.1.5. DTNB Assay
The assay was carried out following the procedure described earlier with a few modifications [44,45].
DTNB was used to quantify the concentration of free thiol groups in the sample. The method is based on the
reaction of this aromatic disulfide with aliphatic thiol groups of a compound to form a mixed disulfide and
2-nitro-5-thiobenzoate (TNB), which ionizes to the TNB2− dianion at neutral or alkaline pH. The reaction
is rapid and stoichiometric, the addition of 1 mol of thiol-containing compound leads to the release of
1 mol of TNB. The latter gives an intense yellow color that can be quantified spectrophotometrically at the
wavelength of 412 nm. The DTNB assay was initiated by mixing 180 µL of 100 µM N-acetyl-L-cysteine
in 0.1 M phosphate buffer solution with either 10 µL of 200 µM, or 1 mM or 2 mM solution of ebselen or
selenazolinium salts exhibiting the highest antibacterial activity in the previous studies (compound 1 and 6),
or hydrogen peroxide, which was used as a positive control in the assay. After 40 min incubation, 10 µL of
DTNB (4 mM) solution was added and the decrease in absorbance was measured spectrophotometrically
by using a microplate reader (EnSpire, PerkinElmer, Waltham, MA, USA) at a wavelength of 412 nm for
10 min at 25 ◦C. One should note that compared to N-acetyl-L-cysteine, the compounds were added in
sub-stoichiometric amounts, as it is possible that such selenium agents react with more than one equivalent
of thiols. It is therefore not expected that all thiols of N-acetyl-L-cysteine are eventually consumed in
this assay.
3.1.6. Ames Test
The alternative Ames test adapted to the HTS microplate format (Xenometrix AG, Allschwil,
Switzerland) was performed using the histidine-dependent Salmonella typhimurium strain TA100,
according to the previously described method of Kamber et al. [25–29]. All the compounds tested
and the reference (ebselen) were evaluated at final concentrations of 1 µM and 10 µM (in the well).
NQNO was applied as a positive standard mutagen control (0.1 µM, 0.5 µM) [29]. Finally, the results
were counted manually and by the use of microplate reader. The mutagenic index (MI) was calculated
next, as the quotient of the number of revertant colonies induced in a test sample and the number
of revertants in a negative control (media with 1% DMSO). A compound is considered mutagenic
if its MI is above 2.0. The Binomial B-values were calculated according to the protocol provided by
Xenometrix AG.
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4. Conclusions
In the present study, a novel group of selenazolinium salts displaying excellent in vitro activity
against ESKAPE pathogens has been described. Similar to ebselen, these reactive selenium species
(RSeS) have demonstrated great potential against 11 strains of S. aureus, including multidrug-resistant
MRSA and VISA clinical isolates. Yet in stark contrast to ebselen, the selenazolinium compounds also
displayed a significant antibacterial action against various members of the Gram-negative ESKAPE
family, including K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli. Moreover, a beneficial
pharmaceutical safety for all selenoazolinium compounds (1–8) has been confirmed in the Ames
mutagenicity assays. These differences between ebselen on one side and the selenazolinium salts on
the other may be explained by differences in reactivity and cellular target(s). Indeed, our preliminary
mechanistic studies indicated that the mode of action for the Se-compounds is likely to be associated
with an alteration of intracellular levels of glutathione and cysteine thiols of different proteins in
the bacterial cells, hence supporting the idea that such compounds interact with the intracellular
thiolstat. Future studies may reveal if this reaction is stoichiometric, or—as anticipated from the low
amounts employed—catalytic with respect to pre-existing ROS and thiols. It is also possible that the
selenazolinium salts react more than once, and that the active species is not the salt itself but possibly a
reactive seleno-sulfide intermediate formed as part of the sequestration by and modification with GSH.
Such investigations may also differentiate between ebselen, which is generally seen as an “antioxidant”
promoting cell survival by reducing ROS in the presence of GSH, and the kind of oxidizing RSeS
employed here, which, due to their high(er) reactivity, seem to attack thiol residues more randomly,
hence modulating the level of GSH yet also affecting proteins and enzymes.
Taking into account such promising properties, we can conclude that the compounds with
the selenazolinium scaffold represent a very promising chemical family in the ongoing search for
new drug candidates that efficiently combat infections caused by highly resistant ESKAPE bacteria.
Thus, the series is worth passing on for further stages of the drug research and development processes
and also for more detailed investigations of the underlying mode(s) of action. At the same time,
the Se–N motif may be refined and “tuned” further to enhance activity and selectivity.
Supplementary Materials: The following are available online. Table S1: Details of MIC values of the compounds
1–8 and ebselen against Gram-negative bacteria, Figure S1: Generation of intracellular ROS in the reference
S. aureus ATCC 25923 strain and in the clinical MRSA HEMSA 5 isolate upon exposure to the different
concentrations of the compound 1, Figure S2: Generation of intracellular ROS in the reference S. aureus ATCC 25923
strain and in the clinical MRSA HEMSA 5 isolate upon exposure to the different concentrations of compound 6,
Figure S3: Generation of intracellular ROS in the reference S. aureus ATCC 25923 strain and in the clinical MRSA
HEMSA 5 isolate upon exposure to the different concentrations of ebselen.
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